Oncology Business Management | Specialty

Rx for Protection Rather Than For Cure

July 17th 2016

Physicians tend to agree that the practice of defensive medicine is widespread, especially in oncology where much more is at stake than in the general practitioner's office. However, things can go drastically wrong.

Oncology Practice Vitality Depends on Leadership

July 16th 2016

The pace of consolidation shows no sign of slowing down, and this trend also applies to oncology, as more and more community-based oncology practices are joining large health systems.

FDA Grants LOXO-101 Breakthrough Designation for Solid Tumors

July 14th 2016

The FDA granted the selective tropomyosin receptor kinase inhibitor LOXO-101 a breakthrough therapy designation for the treatment of adult or pediatric patients with unresectable or metastatic solid tumors with NTRK-infusion proteins who progressed on prior therapy or have no other available treatment options.

New Hampshire Leads Independent Oncology Practice Decline

July 14th 2016

The statistics show you are much more likely to encounter an independent oncology practice in Alaska than in New Hampshire.

CMS Wavers on Commitment to MACRA Reforms

July 14th 2016

The Centers for Medicare & Medicaid Services is wavering on its commitment to the Medicare reform package passed in 2015, based on widespread concerns that the changes may be unwieldy and could increase the pace at which smaller physician practices are being forced into mergers.

Rural Oncology Practices Struggle to Recruit and Retain Employees

July 13th 2016

Pressures on independent oncology practices have been mounting for years, as payer data-reporting requirements become more onerous and revenue from drug reimbursements decline.

Rough Start for Oncology Care Model

July 12th 2016

Many oncology practices were motivated to join the Oncology Care Model in order to keep up with the evolution of value-based care. But when the Center for Medicare & Medicaid Innovation started telling practices that their applications had been accepted, it was panic time for some.

Referring Patients with Colorectal Cancer to Clinical Trials

July 12th 2016

Role of TAS-102 (Trifluridine/tipiracil) in Advanced Colorectal Cancer

July 12th 2016

Colorectal Cancer: Regorafenib Patient Selection and Dosing

July 12th 2016

Goals of Therapy in Refractory Colorectal Cancer

July 12th 2016

Decisions in Colorectal Cancer Maintenance Therapy and Sequencing

July 12th 2016

Right- Versus Left-Sided Colorectal Tumors and Survival

July 12th 2016

Colorectal Cancer: Choosing a Biologic

July 12th 2016

Neoadjuvant and Adjuvant Therapy in Metastatic Colorectal Cancer

July 12th 2016

Goals of Systemic Therapy in Colorectal Cancer

July 12th 2016

Multidisciplinary Approaches in Metastatic Colorectal Cancer

July 12th 2016

Optimizing Care in Metastatic Colorectal Cancer

July 12th 2016

Finding Actionable Biomarkers in Colorectal Cancer

July 12th 2016

Liquid- Vs Tissue-Based Testing in Colorectal Cancer

July 12th 2016